Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Carlyle (CGABL) Liabilities and Shareholders Equity (2016 - 2025)

Carlyle has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $29.1 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $29.1 billion for Q4 2025, up 26.02% from a year ago — trailing twelve months through Dec 2025 was $105.3 billion (up 18.49% YoY), and the annual figure for FY2025 was $29.1 billion, up 26.02%.
  • Liabilities and Shareholders Equity for Q4 2025 was $29.1 billion at Carlyle, up from $27.1 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CGABL hit a ceiling of $29.1 billion in Q4 2025 and a floor of $8.8 billion in Q2 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $21.3 billion (2022), compared with a mean of $21.5 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 58.86% in 2023 and later skyrocketed 152.83% in 2024.
  • Carlyle's Liabilities and Shareholders Equity stood at $21.3 billion in 2021, then grew by 0.72% to $21.4 billion in 2022, then decreased by 1.06% to $21.2 billion in 2023, then rose by 9.1% to $23.1 billion in 2024, then rose by 26.02% to $29.1 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $29.1 billion (Q4 2025), $27.1 billion (Q3 2025), and $25.1 billion (Q2 2025) per Business Quant data.